Compound Reference Overview
| Field | Value |
|---|---|
| Name | Thymosin Alpha-1 |
| Reference Code | TA-1 |
| Category | Healing & Recovery Peptide |
| Example Strength | 1.6 mg vial (varies by manufacturer) |
| Reference Range | 1.6 mg administered 2–3 times weekly (literature reference) |
| Frequency | 2–3 times weekly |
| Key Safety Warning | Immune-modulating peptide. Use caution in autoimmune disease. Avoid in organ transplant recipients receiving immunosuppressive therapy. Approved in some countries (e.g., Zadaxin®) for specific indications. |
Mechanism of Action (Educational)
Thymosin Alpha-1 is a thymic peptide that modulates immune function and enhances T-cell maturation and activity. It influences cytokine signaling, promotes antigen presentation, and supports adaptive immune response regulation.
TA-1 has been studied in viral infections, immune deficiency states, and immune modulation frameworks.
Indications (Literature)
- Approved in some countries for Hepatitis B and C (Zadaxin®)
- Immune enhancement frameworks
- Chronic infection support (investigational)
Administration (Literature)
| Parameter | Details |
|---|---|
| Route | Subcutaneous |
| Frequency | 2–3 times weekly |
| Injection Sites | Abdomen or thigh |
| Timing | Any time; maintain consistent schedule |
Titration Schedule (Literature)
No formal titration required in standard reference frameworks. Typical schedule:
- 1.6 mg administered 2–3 times weekly from initiation
Immune effects are typically observed over several weeks.
Reconstitution & Concentration
(Product-Dependent)
Reconstitution instructions vary by manufacturer. Commercially approved products may include specific diluent volumes and handling instructions. Follow product-specific guidance where applicable.
| Parameter | Value |
|---|---|
| Diluent | Bacteriostatic water or sterile water (product dependent) |
| Example Concentration | Varies by formulation |
| Stability | Up to 28 days refrigerated (if compounded; follow product labeling) |
Safety & Contraindications (Summary)
Contraindications
- Organ transplant recipients on immunosuppressive therapy
- Pregnancy or breastfeeding
Drug Interactions
- Immunosuppressants (high significance): May counteract effects
Adverse Events
- Injection site reactions
- Fatigue
- Mild flu-like symptoms
Serious Risks
- Autoimmune exacerbation (rare)
Monitoring (Literature)
- T-cell counts (if clinically indicated)
- Viral load (where applicable)
- General immune function
Mathematical Calculation Tool
The calculator below allows arithmetic concentration and volume calculations using variable vial strengths and reconstitution volumes.
This tool is provided strictly for mathematical reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Disclaimer
Thymosin Alpha-1 is approved in certain countries for specific indications (e.g., Zadaxin®). This content is provided strictly for educational and professional reference purposes and does not constitute medical advice. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.
Reference Sources
1. Garaci E, et al. Thymosin Alpha-1 in immune modulation.
Ann N Y Acad Sci. 2002; PMID: 12496694.
2. King R, et al. Clinical applications of Thymosin Alpha-1.
Expert Opin Biol Ther. 2007; PMID: 18040895.
3. Liu F, et al. Thymosin Alpha-1 and immune regulation.
Front Immunol. 2017; PMID: 28724174.